EA2174: Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery (clinicaltrials.gov) - Sep 30, 2026 - P2/3 | N=278 | Suspended | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2026 ➔ Mar 2027 | Trial primary completion date: Dec 2026 ➔ Mar 2027
Trial completion date • Trial primary completion date • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor
|